%PDF-1.4
%
70 0 obj
<>
endobj
67 0 obj
<>
endobj
129 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-03-01T09:05:35Z
2024-03-29T06:35:03-07:00
QuarkXPressª: AdobePS 8.8.0 (301)
2024-03-29T06:35:03-07:00
application/pdf
Heather
2003-971.april
uuid:259b3a7f-1dd2-11b2-0a00-6d08278d5b00
uuid:259b3a81-1dd2-11b2-0a00-1e0000000000
endstream
endobj
56 0 obj
<>
endobj
57 0 obj
<>
endobj
71 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 38 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 40 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 42 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 44 0 R/Type/Page>>
endobj
18 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 46 0 R/Type/Page>>
endobj
21 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 48 0 R/Type/Page>>
endobj
32 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 50 0 R/Type/Page>>
endobj
155 0 obj
[159 0 R]
endobj
156 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.0766 Tw 10 0 0 10 53.468 735.6616 Tm
[(the study)64.8 (. )17.7 (While this was not a prospective study)64.8 (, we have)]TJ
0.17419 Tw 0 -1.2 TD
(involved a homogenous group of patients with SLE who)Tj
0.1739 Tw T*
(were followed up for a prolonged period of time. Future)Tj
0.00571 Tc 0.3692 Tw T*
[(prospective analysis should include a lar)17.7 (ger group of)]TJ
-0.00011 Tc 0.0162 Tw T*
(patients with longer duration of followup and the initial site)Tj
0.02499 Tw T*
[(of )17.7 (TB involvement taken into account.)]TJ
/T1_1 1 Tf
0 Tw 0 -2.4 TD
(REFERENCES)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 60.468 641.6616 Tm
[(1.)-875.1 (Baughman RP)110.7 (. )17.7 (The lung in the immunocompromised patient.)]TJ
1.675 -1.25 Td
(Infectious complications. Part 1. Respiration 1999;66:95-109.)Tj
-1.675 -1.25 Td
[(2.)-875.1 (Casado JL, Moreno S, Fortun J, et al. Risk factors for development)]TJ
1.675 -1.25 Td
(of tuberculosis after isoniazid chemoprophylaxis in human )Tj
0 -1.25 TD
(immunodeficiency virus-infected patients. Clin Infect Dis)Tj
0 Tc 0 Tw T*
(2002;34:386-9.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(3.)-875.1 (Hall CM, )17.7 (W)39.8 (ilcox P)91.7 (A, Swanepoel CR, Kahn D, )17.7 (V)110.8 (an Zyl Smit R.)]TJ
1.675 -1.25 Td
(Mycobacterial infection in renal transplant patient. Nephron)Tj
0 Tc 0 Tw T*
(1980;26:187-8.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(4.)-875.1 (Qunibi )17.7 (WY)128.8 (, )54.8 (Al-Sibai MD, )17.7 (T)69.9 (aher S, et al. Mycobacterial infection)]TJ
1.675 -1.25 Td
(after renal transplantation \321 report of 14 cases and review of the)Tj
T*
(literature. QJM 1990;282:1039-60.)Tj
-1.675 -1.25 Td
[(5.)-875.1 (Riminton S, Pearce N, )54.8 (Antony B. )17.7 (T)35 (uberculosis and treatment with)]TJ
1.675 -1.25 Td
(infliximab. New Engl J Med 2002;346:623-6.)Tj
-1.675 -1.25 Td
[(6.)-875.1 (Keane J, Gershon S, )17.7 (W)39.8 (ise RP)110.7 (, et al. )17.7 (T)35 (uberculosis associated with)]TJ
1.675 -1.25 Td
(infliximab, a tumor necrosis factor alpha-neutralizing agent. New)Tj
0 Tc T*
(Engl J Med 2001;345:1098-104.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(7.)-875.1 (De Pinho )54.8 (AM, Santoro-Lopes G, Harrison LH, Schechter M.)]TJ
1.675 -1.25 Td
[(Chemoprophylaxis for tuberculosis and survival of HIV)91.7 (-infected)]TJ
T*
[(patients in Brazil. )54.8 (AIDS 2001;15:2129-35.)]TJ
-1.675 -1.25 Td
[(8.)-875.1 (Porter JDH, McAdam KPWJ. )17.7 (T)35 (uberculosis in )54.8 (Africa in the )54.8 (AIDS)]TJ
1.675 -1.25 Td
[(era: the role of chemoprophylaxis. )17.7 (T)35 (rans R Soc )17.7 (T)35 (rop Med Hyg)]TJ
0 Tc 0 Tw T*
(1992;86:467-9.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(9.)-875.1 (International Union )54.8 (Against )17.7 (T)35 (uberculosis. Ef)17.7 (ficacy of various )]TJ
1.675 -1.25 Td
[(duration of isoniazid preventive therapy for tuberculosis: Five )36.7 (Y)99.8 (ears)]TJ
T*
[(of Follow-up IUA)110.7 (T)-239.3 (T)35 (rial. Bull )17.7 (WHO 1982;60:555-64.)]TJ
-2.175 -1.25 Td
[(10.)-875.1 (Fitzgerald DW)91.7 (, Desvarieux M, Severe P)110.7 (,)-0.1 ( Joseph P)110.7 (,)-0.1 ( Johnson )17.7 (WD Jr)39.7 (,)]TJ
2.175 -1.25 Td
[(Pape JW)91.7 (. Ef)17.7 (fect of post-treatment isoniazid on prevention of )]TJ
T*
[(recurrent tuberculosis in HIV)91.7 (-1-infected individuals: a randomised)]TJ
T*
(trial. Lancet 2000;356:1470-4.)Tj
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Centers for Disease Control and Prevention. )17.7 (The use of preventive)]TJ
2.1381 -1.25 Td
(therapy for tuberculous infection in the United States:)Tj
T*
[(Recommendations for the )54.8 (Advisory Committee for the Elimination)]TJ
T*
[(of )17.7 (T)35 (uberculosis. Morb Mortal )17.7 (Wkly Rep 1990;39:9-12.)]TJ
-2.175 -1.25 Td
[(12.)-875.1 (T)69.9 (erry Beirn Community Programs for Clinical Research on )54.8 (AIDS,)]TJ
2.175 -1.25 Td
[(the )54.8 (Adult )54.8 (AIDS Clinical )17.7 (T)35 (rial Group, the P)91.7 (AN )54.8 (American Health)]TJ
T*
[(Or)17.7 (ganisation and the Centers for Disease Control and Prevent)]TJ
T*
(Study Group. Rifampin and pyrazinamide vs isoniazid for )Tj
T*
[(prevention of tuberculosis in HIV)91.7 (-infected persons: an international)]TJ
T*
[(randomized trial. JAMA)-220.1 (200;283:1445-50.)]TJ
-2.175 -1.25 Td
[(13.)-875.1 (American )17.7 (Thoracic Society)64.9 (. )17.7 (T)35 (reatment of tuberculosis and )]TJ
2.175 -1.25 Td
[(tuberculosis infection in adults and children. )54.8 (Am J Respir Crit Care)]TJ
0 Tc T*
(Med 1994;149:1359-74.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(14.)-875.1 (Joint )17.7 (T)35 (uberculosis Committee of the British )17.7 (Thoracic Society)64.9 (.)]TJ
2.175 -1.25 Td
(Chemotherapy and management of tuberculosis in the United)Tj
T*
[(Kingdom: recommendations 1998. )17.7 (Thorax 1998;53:536-58.)]TJ
-2.175 -1.25 Td
[(15.)-875.1 (Israel HL, Gottlieb JE, Maddrey )17.7 (WC. Perspectives: Prevention )]TJ
2.175 -1.25 Td
[(isoniazid therapy and the liver)54.8 (. Chest 1992;101:1298-31.)]TJ
-2.175 -1.25 Td
[(16.)-875.1 (Snider DE Jr)39.7 (, Caras GJ. Isoniazid-associated hepatitis deaths: )54.8 (A)]TJ
2.175 -1.25 Td
[(review of available information. )54.8 (Am Rev Respir Dis )]TJ
0 Tc 0 Tw T*
(1992;145:494-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(17.)-875.1 (T)69.9 (an EM, Cohen )54.8 (AS, Fries JF)79.7 (, et al. )17.7 (The 1982 revised criteria for the)]TJ
2.175 -1.25 Td
[(classification of systemic lupus erythematosus. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1982;25:1271-7.)Tj
-0.00011 Tc 0.02499 Tw 30.825 78.171 Td
[(18.)-875.1 (Bayer R, )17.7 (W)39.9 (ilkinson D. Directly observed therapy for tuberculosis:)]TJ
2.175 -1.25 Td
(history of an idea. Lancet 1995;345:1545-9.)Tj
-2.175 -1.25 Td
[(19.)-875.1 (Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH,)]TJ
2.175 -1.25 Td
(and the Committee on Prognosis Studies in SLE. Derivation of the)Tj
T*
[(SLEDAI. )54.8 (A)-220.1 (disease activity index for lupus patients. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 1992;35:630-40.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(20.)-875.1 (Chang KC, Leung CC, )17.7 (T)69.9 (am CM. Recent trend of tuberculosis in)]TJ
2.175 -1.25 Td
[(Hong Kong. Pub Health Epidemiol Bull 2002;1)36.8 (1:69-75.)]TJ
-2.175 -1.25 Td
[(21.)-875.1 (Hernandez-Cruz B, Sifuentes-Osornio J, Ponce-de-leon-Rosales S,)]TJ
2.175 -1.25 Td
[(Ponce-de-Leon-Garduno )54.8 (A, Diaz-Jouanen E. Mycobacterium )]TJ
T*
(tuberculosis infection in patients with systemic rheumatic diseases.)Tj
T*
[(A)-220.1 (case-series. Clin Exp Rheumatol 1999;17:289-96.)]TJ
-2.175 -1.25 Td
[(22.)-875.1 (Balakrishnan C, Mangat G, Mittal G, Joshi )17.7 (VR. )17.7 (T)35 (uberculosis in)]TJ
2.175 -1.25 Td
[(patients with systemic lupus erythematosus. J )54.8 (Assoc Physicians)]TJ
T*
(India 1998;46:682-3.)Tj
-2.175 -1.25 Td
[(23.)-875.1 (Feng PH, )17.7 (T)69.9 (an )17.7 (TH. )17.7 (T)35 (uberculosis in patients with systemic lupus )]TJ
2.175 -1.25 Td
[(erythematosus. )54.9 (Ann Rheum Dis 1982;41:1)36.8 (1-4.)]TJ
-2.175 -1.25 Td
[(24.)-875.1 (Raj SM, Hunt J. Systemic lupus erythematosus and miliary )]TJ
2.175 -1.25 Td
(tuberculosis in a prepubertal girl \321 a case report. Med J Malaysia)Tj
0 Tc 0 Tw T*
(1990;45:347-8.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(25.)-875.1 (Rovensky J, Kovalancik M, Kristufek P)110.7 (, et al. Contribution to the)]TJ
2.175 -1.25 Td
(problem of occurrence of tuberculosis in patients with systemic)Tj
T*
(lupus erythematosus. Z Rheumatol 1996;55:180-7.)Tj
0.00729 Tw -2.175 -1.25 Td
[(26.)-875.1 (V)59.8 (ictorio-Navarra )-17.7 (ST)73.9 (, )-17.8 (Dy )-17.8 (EE, )37.1 (Arroyo )-17.7 (CG, T)69.9 (orralba TP)110.7 (. T)35 (uberculosis)]TJ
0.02499 Tw 2.175 -1.25 Td
(among Filipino patients with systemic lupus erythematosus. Semin)Tj
T*
(Arthritis Rheum 1996;26:628-34.)Tj
-2.175 -1.25 Td
[(27.)-875.1 (Paton NI. Infections in systemic lupus erythematosus patients. )54.8 (Ann)]TJ
2.175 -1.25 Td
(Acad Med Singapore 1997;26:694-700.)Tj
-2.175 -1.25 Td
[(28.)-875.1 (Kim HA, )36.8 (Y)99.8 (oo CD, Baek HJ, et al. Mycobacterium tuberculosis)]TJ
2.175 -1.25 Td
(infection in a corticosteroid-treated rheumatic disease patient )Tj
T*
(population. Clin Exp Rheumatol 1998;16:9-13.)Tj
-2.175 -1.25 Td
[(29.)-875.1 (Coutts II, Jegarajah S, Stark JE. )17.7 (T)35 (uberculosis in renal transplant)]TJ
2.175 -1.25 Td
(recipients. Br J Dis Chest 1979;73:141-8.)Tj
-2.175 -1.25 Td
[(30.)-875.1 (Nef)17.7 (f )17.7 (T)79.9 (A, Hudgel DW)91.7 (. Miliary tuberculosis in a renal transplant)]TJ
2.175 -1.25 Td
[(recipient. )54.8 (Am Rev Respir Dis 1973;108:677-8.)]TJ
-2.175 -1.25 Td
[(31.)-875.1 (Andonopoulos )54.8 (AP)110.7 (, Safridi C, Karokis D, Bounas )54.8 (A. Is a purified)]TJ
2.175 -1.25 Td
(protein derivative skin test and subsequent antituberculous )Tj
T*
(chemoprophylaxis really necessary in systemic rheumatic disease)Tj
T*
(patients receiving corticosteroid? Clin Rheumatol 1998;17:181-5.)Tj
-2.175 -1.25 Td
[(32.)-875.1 (Higgins RM, Cahn )54.8 (AP)110.8 (, Porter D, et al. Mycobacterial infection after)]TJ
2.175 -1.25 Td
(renal transplantation. QJM 1992;286:145-53.)Tj
-2.175 -1.25 Td
[(33.)-875.1 (John GT)73.9 (, )17.7 (Thomas PP)110.7 (, )17.7 (Thomas M, Jeyaseelan L, Jacob CK, Shastry)]TJ
2.175 -1.25 Td
[(JCM. )54.8 (A)-220.1 (double-blind randomized controlled trial of primary )]TJ
T*
(isoniazid prophylaxis in dialysis and transplant patients.)Tj
T*
[(T)35 (ransplantation 1994;87:1683-4.)]TJ
-2.175 -1.25 Td
[(34.)-875.1 (Apaydin S, )54.8 (Altiparmak MR, Serdengecti K, )54.8 (Ataman R, Ozturk R,)]TJ
2.175 -1.25 Td
(Erek E. Mycobacterium tuberculosis infections after renal )Tj
T*
(transplantation. Scand J Infect Dis 2000;32:501-5.)Tj
-2.175 -1.25 Td
[(35.)-875.1 (Singh N, )17.7 (W)79.9 (agener MM, Gayowski )17.7 (T)74 (. Safety and ef)17.7 (ficacy of )]TJ
2.175 -1.25 Td
(isoniazid chemoprophylaxis administered during liver transplant)Tj
T*
(candidacy for the prevention of posttransplant tuberculosis.)Tj
T*
[(T)35 (ransplantation 2002;74:892-5.)]TJ
-2.175 -1.25 Td
[(36.)-875.1 (Hernandez-Cruz B, Ponce-de-leon-Rosales S, Sifuentes-Osornio )]TJ
2.175 -1.25 Td
[(J, Ponce-de-Leon-Garduno )54.8 (A, Diaz-Jouanen E. )17.7 (T)35 (uberculosis )]TJ
T*
(prophylaxis in patients with steroid treatment and systemic )Tj
T*
[(rheumatic disease. )54.8 (A)-220.1 (case control study)64.9 (. Clin Exp Rheumatol)]TJ
0 Tc 0 Tw T*
(1999;17:81-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(37.)-875.1 (Gaitonade S, Pathan E, Sule )54.8 (A, Mittal G, Joshi )17.7 (VR. Ef)17.7 (ficacy of )]TJ
2.175 -1.25 Td
(isoniazid prophylaxis in patients with systemic lupus erythematosus)Tj
T*
[(receiving long term steroid treatment. )54.8 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
(2002;61:251-3.)Tj
ET
0 0 0 1 K
53.468 76.5 m
558.468 76.5 l
S
0 0 0 0 k
494.29 69.365 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_2 1 Tf
8 0 0 8 545.468 56.4344 Tm
(615)Tj
ET
0 0 0 0 k
53.532 70.5 203 -15.665 re
f*
BT
0 0 0 1 k
/T1_2 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.532 57.5695 Tm
[(Mok, et al: aPL)-257.3 (antibodies in SLE)]TJ
ET
0 0 0 0 k
/GS0 gs
102.631 81.25 407.5 -10.833 re
f*
0.5 w
/GS1 gs
102.631 81.25 407.5 -10.833 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_3 8 Tf
108.828 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
50 0 obj
<>stream
8;Z\6>B8aX%-.:>aQr3Z`->+EA=L^7UDn@0VC=*K+:'=cH[aA!m_R0B1`-$_Ej+2S01e\>>D%9OjWX.Skr.!>n/,Z35iBki1Zpj0CKrlZmgd)2Nb>RMJ0u`\"-i$::Da
,[`ot=m!$GCeOiK#5?@_a"X/^2))sIEY+SY_Wr&FlHOZEHq*Mq"R8gJ(tKs9YIKcl
5//bFfTH.uHpI-CS6F__\OK"de.m%)\3<=hk4n2?736N:Ra05:)C+P4j#G;80*Y-T
jIh!:d_<)?"s_"7]^+7ZHetR<+I-*ZDsg#<'??i4e:$0W40;B@;HYR$jEFURrEM+/
7-@"a89Ei"+"S9a9ck4_#[q`2/G>&(0`PVZ6>[d=i@-;&`0FUdA&5iE;TeW)$1!=3
@:74XosinV;B$J:c"c=oCTul2FkY1ECflL1jdE?LB(NZ=6(RHPAAt%LJi*7E]V>;'
H0r_t=cmn@;QBY6Z8-K_leFQ"]T.J['ObheF@Zq/?+]L?]a!:Q/h(9tVuhTVAS)/E
1uY*q9q\UW9#?,-Bb7T/Mj[_B-=->agH&:n2Ke/Gs20OW^+P1,PEYlYV-P]*"Q<%Sj6O]@KA;
q1H13Xdbl@\6if*`2,RJ6Et,)X_k\A<(HW$BK9nZ%i\ji)*oWla)a>O8`Z=FfKJts
TbnOSLJ!4P'qn9sTap[5DE>97p2%bgRd7;mDPhc2P2_q3#6?LL3#a']BZBhC761Ci
Ao/kmJR(k(lC)nCA6^3(],-j191-b>5L+%$PoCZD]l*oNfnm^OhU51!YAi0,Cs9k"
8Dga7Ig,o0\8"A~>
endstream
endobj
54 0 obj
[/Indexed/DeviceRGB 255 53 0 R]
endobj
53 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
79 0 obj
<>
endobj
35 0 obj
<>
endobj
74 0 obj
<>
endobj
114 0 obj
<>
endobj
134 0 obj
<>
endobj
73 0 obj
<>
endobj
109 0 obj
<>stream
Ht{PwgYfv\dřQ|@|AT*AEWy,wXax (+AQ䰈&SN|D$U㥇4Uw?_~ݿ>2ֆdKV%hWDbBtlDN.rOF9؈._~U\foA]p邻PM2DkoItn3K[;k.xkƬS+O7hĘ$>#BX5j
:-c цBRZ
Btb$vuhNkoվ]|B&}oC8QkCL/! **ϒ eJOdnژlu'^Oj1դT*3_mk)>ۍOZEqc NN}U3/<߹Wy+0ҭOP *Ȕ4ua
OفZp?^V;I\s78. >i2[p9`ֱ ፞;τ;QEШJdn]W dZtE\R-%ȒC|`=rA.;r?rTrsBWnjU'G'e}9ȃadׁ]Q
y\;ѣϰ!r*sKUWҝ\R[SYQρXCTTkOȏW2Hyo~qVI.hnvdLB7x|X&